TANGO THERAPEUTICS INC (TNGX) Fundamental Analysis & Valuation

NASDAQ:TNGX • US87583X1090

Current stock price

17.3 USD
+0.15 (+0.87%)
At close:
17.35 USD
+0.05 (+0.29%)
Pre-Market:

This TNGX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TNGX Profitability Analysis

1.1 Basic Checks

  • TNGX had negative earnings in the past year.
  • TNGX had a negative operating cash flow in the past year.
  • In the past 5 years TNGX always reported negative net income.
  • In the past 5 years TNGX always reported negative operating cash flow.
TNGX Yearly Net Income VS EBIT VS OCF VS FCFTNGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -50M -100M

1.2 Ratios

  • With a decent Return On Assets value of -25.48%, TNGX is doing good in the industry, outperforming 70.46% of the companies in the same industry.
  • TNGX has a better Return On Equity (-29.35%) than 75.48% of its industry peers.
Industry RankSector Rank
ROA -25.48%
ROE -29.35%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TNGX Yearly ROA, ROE, ROICTNGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • TNGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNGX Yearly Profit, Operating, Gross MarginsTNGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. TNGX Health Analysis

2.1 Basic Checks

  • TNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for TNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TNGX Yearly Shares OutstandingTNGX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TNGX Yearly Total Debt VS Total AssetsTNGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 24.72 indicates that TNGX is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 24.72, TNGX belongs to the top of the industry, outperforming 90.93% of the companies in the same industry.
  • TNGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 24.72
ROIC/WACCN/A
WACC8.92%
TNGX Yearly LT Debt VS Equity VS FCFTNGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • TNGX has a Current Ratio of 16.32. This indicates that TNGX is financially healthy and has no problem in meeting its short term obligations.
  • TNGX's Current ratio of 16.32 is amongst the best of the industry. TNGX outperforms 92.86% of its industry peers.
  • TNGX has a Quick Ratio of 16.32. This indicates that TNGX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of TNGX (16.32) is better than 92.86% of its industry peers.
Industry RankSector Rank
Current Ratio 16.32
Quick Ratio 16.32
TNGX Yearly Current Assets VS Current LiabilitesTNGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. TNGX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 28.93% over the past year.
  • TNGX shows a strong growth in Revenue. In the last year, the Revenue has grown by 48.29%.
  • TNGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.89% yearly.
EPS 1Y (TTM)28.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.14%
Revenue 1Y (TTM)48.29%
Revenue growth 3Y35.89%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.52% on average over the next years. This is quite good.
  • Based on estimates for the next years, TNGX will show a very strong growth in Revenue. The Revenue will grow by 49.95% on average per year.
EPS Next Y-48.58%
EPS Next 2Y-28.86%
EPS Next 3Y-11.54%
EPS Next 5Y17.52%
Revenue Next Year-82.14%
Revenue Next 2Y-54.92%
Revenue Next 3Y16.87%
Revenue Next 5Y49.95%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TNGX Yearly Revenue VS EstimatesTNGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
TNGX Yearly EPS VS EstimatesTNGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

0

4. TNGX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TNGX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNGX Price Earnings VS Forward Price EarningsTNGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNGX Per share dataTNGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A cheap valuation may be justified as TNGX's earnings are expected to decrease with -11.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.86%
EPS Next 3Y-11.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TNGX Dividend Analysis

5.1 Amount

  • TNGX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TNGX Fundamentals: All Metrics, Ratios and Statistics

TANGO THERAPEUTICS INC

NASDAQ:TNGX (3/13/2026, 8:00:37 PM)

Premarket: 17.35 +0.05 (+0.29%)

17.3

+0.15 (+0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-11
Inst Owners127.67%
Inst Owner Change17.19%
Ins Owners1.54%
Ins Owner Change-2.42%
Market Cap2.33B
Revenue(TTM)62.38M
Net Income(TTM)-101.59M
Analysts85.88
Price Target15.19 (-12.2%)
Short Float %36.95%
Short Ratio14.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)185.6%
Min EPS beat(2)11.15%
Max EPS beat(2)360.05%
EPS beat(4)3
Avg EPS beat(4)92.93%
Min EPS beat(4)-0.84%
Max EPS beat(4)360.05%
EPS beat(8)5
Avg EPS beat(8)52.56%
EPS beat(12)8
Avg EPS beat(12)40.48%
EPS beat(16)10
Avg EPS beat(16)31.72%
Revenue beat(2)1
Avg Revenue beat(2)-28.98%
Min Revenue beat(2)-100%
Max Revenue beat(2)42.04%
Revenue beat(4)1
Avg Revenue beat(4)-33.07%
Min Revenue beat(4)-100%
Max Revenue beat(4)42.04%
Revenue beat(8)3
Avg Revenue beat(8)2.88%
Revenue beat(12)5
Avg Revenue beat(12)10.13%
Revenue beat(16)6
Avg Revenue beat(16)8.66%
PT rev (1m)11.32%
PT rev (3m)12.37%
EPS NQ rev (1m)-3.48%
EPS NQ rev (3m)-3.48%
EPS NY rev (1m)0.18%
EPS NY rev (3m)-3.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-32.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 37.32
P/FCF N/A
P/OCF N/A
P/B 6.73
P/tB 6.73
EV/EBITDA N/A
EPS(TTM)-0.86
EYN/A
EPS(NY)-1.28
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS0.46
BVpS2.57
TBVpS2.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.48%
ROE -29.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 45.94%
Cap/Sales 1.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.32
Quick Ratio 16.32
Altman-Z 24.72
F-Score5
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)46.44%
Cap/Depr(5y)164.28%
Cap/Sales(3y)2.55%
Cap/Sales(5y)8.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.14%
EPS Next Y-48.58%
EPS Next 2Y-28.86%
EPS Next 3Y-11.54%
EPS Next 5Y17.52%
Revenue 1Y (TTM)48.29%
Revenue growth 3Y35.89%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-82.14%
Revenue Next 2Y-54.92%
Revenue Next 3Y16.87%
Revenue Next 5Y49.95%
EBIT growth 1Y23.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-76.76%
EBIT Next 3YN/A
EBIT Next 5Y13.76%
FCF growth 1Y-5.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.62%
OCF growth 3YN/A
OCF growth 5YN/A

TANGO THERAPEUTICS INC / TNGX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of TANGO THERAPEUTICS INC (TNGX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to TNGX.


What is the valuation status of TANGO THERAPEUTICS INC (TNGX) stock?

ChartMill assigns a valuation rating of 0 / 10 to TANGO THERAPEUTICS INC (TNGX). This can be considered as Overvalued.


What is the profitability of TNGX stock?

TANGO THERAPEUTICS INC (TNGX) has a profitability rating of 1 / 10.